CA2233558A1 - Method and pharmaceutical composition for regulating lipid concentration - Google Patents
Method and pharmaceutical composition for regulating lipid concentrationInfo
- Publication number
- CA2233558A1 CA2233558A1 CA002233558A CA2233558A CA2233558A1 CA 2233558 A1 CA2233558 A1 CA 2233558A1 CA 002233558 A CA002233558 A CA 002233558A CA 2233558 A CA2233558 A CA 2233558A CA 2233558 A1 CA2233558 A1 CA 2233558A1
- Authority
- CA
- Canada
- Prior art keywords
- combination
- methylethyl
- pharmaceutical composition
- lipid concentration
- regulating lipid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002632 lipids Chemical class 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000001105 regulatory effect Effects 0.000 title 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- -1 2,6-bis(1-methylethyl)phenyl ester Chemical class 0.000 abstract 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 abstract 1
- 229940121710 HMGCoA reductase inhibitor Drugs 0.000 abstract 1
- 238000008214 LDL Cholesterol Methods 0.000 abstract 1
- 102000004895 Lipoproteins Human genes 0.000 abstract 1
- 108090001030 Lipoproteins Proteins 0.000 abstract 1
- 239000007983 Tris buffer Substances 0.000 abstract 1
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 abstract 1
- 230000000923 atherogenic effect Effects 0.000 abstract 1
- 229960005370 atorvastatin Drugs 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 230000001419 dependent effect Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 210000003989 endothelium vascular Anatomy 0.000 abstract 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention is a combination of an ACAT inhibitor for example, sulfamic acid, [[2,4,6; tris(1-methylethyl)phenyl]acetyl]-, 2,6-bis(1-methylethyl)phenyl ester, and an HMG-CoA-reductase inhibitor, for example, atorvastatin, effective for lipid regulation. The combination of agents results in a greater reduction in plasma VLDL and LDL
cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoprotein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.
cholesterol and increases HDL cholesterol than either alone resulting in a less atherogenic lipoprotein profile. The combination is useful in the treatment of patients with or at risk of developing ischemic syndromes in order to restore endogenous vascular endothelium-dependent activities.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US615595P | 1995-11-02 | 1995-11-02 | |
| US60/006,155 | 1995-11-02 | ||
| PCT/US1996/015854 WO1997016184A1 (en) | 1995-11-02 | 1996-10-02 | Method and pharmaceutical composition for regulating lipid concentration |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2233558A1 true CA2233558A1 (en) | 1997-05-09 |
| CA2233558C CA2233558C (en) | 2005-12-06 |
Family
ID=35519705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002233558A Expired - Fee Related CA2233558C (en) | 1995-11-02 | 1996-10-02 | Method and pharmaceutical composition for regulating lipid concentration |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2233558C (en) |
-
1996
- 1996-10-02 CA CA002233558A patent/CA2233558C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2233558C (en) | 2005-12-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NZ512484A (en) | Regulating lipid concentration in mammals by administering an acyl-CoA cholesterol O-acyltransferase (ACAT) inhibitor and an HMG-CoA reductase inhibitor | |
| FI951218A0 (en) | Method for reducing blood levels of total cholesterol and low-density lipoprotein cholesterol | |
| AU3720295A (en) | Ribozyme treatment of diseases or conditions related to levels of plasma lipoprotein (a) {lp(a)} by inhibiting apolipoprotein (a) {apo(a)} | |
| CA2088254A1 (en) | Treatment for hypercholesterolemia | |
| LU91253I2 (en) | Pharmaceutical composition comprising amlodipine or an atorvastatin salt or a salt thereof and a carrier or diluent | |
| BG101993A (en) | Dialkylethers containing end carboxylic or tetrazole groups | |
| CA2210996A1 (en) | Liquid formulations for proteinic pharmaceuticals | |
| AU5074196A (en) | Method for preventing a second heart attack employing an HMG CoA reductase inhibitor | |
| MX9801159A (en) | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions. | |
| AU7217594A (en) | Method and composition for treatment of abnormal conditions of the epithelium of bodily orifices | |
| AU6311694A (en) | Device for the direct measurement of low density lipoprotein cholesterol | |
| AU702443C (en) | Method for determinaton of cholesterol in low-density lipoprotein | |
| NO862750D0 (en) | PROCEDURE FOR THE PREPARATION OF PHARMACOLOGICALLY ACTIVE OXINDOL DERIVATIVES. | |
| CA2198535A1 (en) | Method of increasing testosterone | |
| NO995928L (en) | Alpha-1-antitrypsin preparations and their method of preparation | |
| Bergt et al. | Hypochlorite modification of high density lipoprotein: effects on cholesterol efflux from J774 macrophages | |
| CA2233558A1 (en) | Method and pharmaceutical composition for regulating lipid concentration | |
| WO1998005291A3 (en) | Method for treating mental retardation | |
| CA2049119A1 (en) | Lipoprotein removal by soluble enzymes | |
| Luoma et al. | Lipid peroxides, glutathione peroxidase, high density lipoprotein subfractions and apolipoproteins in young adults | |
| NO934832L (en) | Pharmaceutical composition for the prevention or treatment of arterioscherosis | |
| AU4525796A (en) | Methods and materials for the immunoassay of apolipoprotein(a) and lipoprotein(a) | |
| AU7533194A (en) | Use of centrally effective alpha-2 agonists for inhibiting postaggression metabolism | |
| Galle et al. | Oxidized lipoprotein (a) inhibits endothelium-dependent dilation: prevention by high density lipoprotein | |
| WO2001041706A3 (en) | Lipid nanotubules for topical delivery |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |